Skip to main content
. 2022 Aug 30;7(36):32131–32152. doi: 10.1021/acsomega.2c03368

Table 1. Inhibitory Activity of the Compound on BACE1 and GSK3β.

compound inhibitiona(%, hBACE1) inhibitionb(%, hGSK3β) compound inhibitiona(%, hBACE1) inhibitionb(%, hGSK3β)
A1 34 ± 1 35 ± 1 B6 13 ± 1 37 ± 1
A2 55 ± 1 34 ± 1 B7 60 ± 1 34 ± 1
A3 30 ± 1 36 ± 1 B8 33 ± 2 34 ± 1
A4 38 ± 1 35 ± 1 C1 36 ± 1 38 ± 1
A5 24 ± 1 36 ± 1 C2 33 ± 1 39 ± 1
A6 12 ± 1 36 ± 1 C3 46 ± 1 38 ± 1
A7 46 ± 1 33 ± 1 C4 40 ± 1 38 ± 1
A8 46 ± 1 37 ± 1 C5 26 ± 1 40 ± 1
A9 33 ± 1 36 ± 1 C6 42 ± 1 38 ± 1
B1 34 ± 1 34 ± 1 C7 31 ± 1 39 ± 1
B2 29 ± 1 35 ± 1 C8 40 ± 1 38 ± 1
B3 34 ± 1 35 ± 1 C9 40 ± 1 40 ± 1
B4 34 ± 1 34 ± 1 C10 41 ± 1 40 ± 1
B5 54 ± 1 37 ± 1 C11 62 ± 1 44 ± 1
notopterolc 45 ± 1 30 ± 1 LY2811376d 52 ± 1 inactive
staurosporinee inactive 62 ± 1      
a

Inhibition percentage of hBACE1 at 20 μM.

b

Inhibition percentage of hGSK3β at 10 μM.

c

The concentration of notopterol for hBACE1 is 20 μM, and for hGSK3β is 10 μM.

d

The concentration of LY2811376 is 5.0 μM.

e

The concentration of staurosporine is 1.0 μM.